Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.19

€7.19

-1.960%
-0.135
-1.960%
€8.50

€8.50

 
30.04.24 / Tradegate WKN: A2QA48 / Name: Actinium Pharmaceuticals / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
28.04.24
11.47%
buy
19.04.24
11.91%
buy
€10.00
17.03.24
10.33%
buy
€7.00
04.02.24
40.19%
buy
Best running prediction
€7.00
04.02.24
40.19%
buy
Your prediction

Actinium Pharmaceuticals Inc. Stock

We can see a decrease in the price for Actinium Pharmaceuticals Inc.. Compared to yesterday it has lost -€0.135 (-1.960%).
Currently there is a rather positive sentiment for Actinium Pharmaceuticals Inc. with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 8 € shows a slightly positive potential of 11.27% compared to the current price of 7.19 € for Actinium Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Actinium Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Actinium Pharmaceuticals Inc. in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Actinium Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Actinium Pharmaceuticals Inc. -1.960% 8.939% -2.177% -10.125% 59.071% 12.344% -
Immunic Inc. 5.600% 2.686% -3.580% -21.627% -17.133% -90.735% -
NanoViricides Inc. 7.770% 6.731% 6.731% -1.770% 17.460% -67.468% -73.907%
Ocuphire Pharma Inc. 5.110% 9.477% -16.685% -67.029% -44.615% - -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-13

This analysis presents an overview of the financial performance of Actinium Pharmaceuticals, an industry leader in Biotechnology & Medical Research. Its financial statements and ratios reveal an intricate blend of strengths and weaknesses, which, to the keen observer, offer various avenues for exploration and critical assessment.

Notabily, the company's market capitalization stands at 122.93 million USD. Well, any entrepreneur would attest that a hefty market capitalization, such as Actinium's, suggests that the market holds a strong confidence in a company’s long-term prospects. Ergo, this benchmark underscores Actinium’s potential to spark its investors' trust.

Call it a cliché, but it's not all about the money. However, business, specifically in Biotechnology & Medical Research, often requires grand financial floatation devices. Actinium has an enterprise value of 37.65 million, a respectable figure in its industry. This figure indicates a commendable ability on Actinium's part to generate revenues, displaying significant proficiency in business operations quite a relief to both existing and potential investors.